NEW ORLEANS – The sponsors of the Cardiomems heart failure monitoring system have struggled to gain acceptance from public payers, but data from a U.S. FDA-mandated post-approval study show that the device reduced hospital readmissions by 58 percent, a set of data that could finally tilt the field for coverage decisively in the device's direction.